Although chemotherapy remains the benchmark for drug development in pancreatic cancer, signals seen with selective KRAS-targeted agents, PARP inhibitors, and metabolic agents suggest that novel approaches do have the ability to prolong survival in the advanced setting, explained Eileen O’Reilly, MD.
“It’s exciting times in pancreas cancer. We’re seeing some very interesting science being translated into the clinic,” said O’Reilly, Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), Read more . . .